Daré Bioscience, Inc. (DARE)
NASDAQ: DARE · Real-Time Price · USD
0.7210
0.00 (0.00%)
At close: Sep 4, 2026, 4:00 PM EDT
0.7300
+0.0090 (1.25%)
Pre-market: Sep 8, 2026, 7:00 AM EDT
Daré Bioscience Revenue
Daré Bioscience had revenue of $187.55K in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $1.37M. In the year 2025, Daré Bioscience had annual revenue of $1.03M with 10,429.36% growth.
Revenue (ttm)
$1.37M
Revenue Growth
+10,429.36%
P/S Ratio
8.07
Revenue / Employee
$56,914
Employees
24
Market Cap
11.02M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.03M | 1.02M | 10,429.36% |
| Dec 31, 2024 | 9.78K | -2.80M | -99.65% |
| Dec 31, 2023 | 2.81M | -7.19M | -71.92% |
| Dec 31, 2022 | 10.00M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | 80.00K | 74.00K | 1,233.33% |
| Dec 31, 2013 | 6.00K | -619.00K | -99.04% |
| Dec 31, 2012 | 625.00K | 619.00K | 10,316.67% |
| Dec 31, 2011 | 6.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Xenetic Biosciences | 3.26M |
| Vistagen Therapeutics | 2.50M |
| CytoMed Therapeutics | 669.28K |
| Senti Biosciences Holdings | 55.00K |
| Kiora Pharmaceuticals | 20.00K |
| Azitra | 7.50K |
DARE News
- 7 days ago - Dare Bioscience announces new $908,000 NIH funding award to advance DARE-PTB2 - TheFly
- 7 days ago - Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth - GlobeNewsWire
- 11 days ago - Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series - GlobeNewsWire
- 12 days ago - Daré Bioscience Transcript: Investor update - Transcripts
- 12 days ago - Daré Bioscience's Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Society - GlobeNewsWire
- 13 days ago - Daré Bioscience Registration statement: Registration filing - Filings
- 13 days ago - Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment - GlobeNewsWire
- 20 days ago - DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List - GlobeNewsWire